Tirzepatide Dosage Chart: The FDA Titration Schedule

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — plain-language guidance on GLP-1 therapies, weight-management protocols, and the genetic variables behind every metabolic decision.

People searching for a tirzepatide dosage chart are usually mapping where they sit — or expect to sit — on the titration ladder. This page explains what the FDA-approved label describes about that schedule and what patients commonly report along the way. It contains no prescribing or titration direction; that role belongs to your prescribing provider.

What the dosage chart actually represents

A dosage chart is a visual of the FDA-label titration schedule, not a menu to choose from. Tirzepatide is titrated per the label starting at 2.5 mg weekly and moving through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals. The chart exists to show the ordered steps; where any individual lands on it is decided by a provider based on tolerability and clinical response.

Why the schedule climbs in steps

The stepwise structure is deliberate. Starting low and increasing gradually gives the body time to adjust and helps limit the gastrointestinal effects that are most pronounced early after each increase.

The starting rung

The initial step establishes tolerance rather than targeting a clinical endpoint, which is why it is the same entry point regardless of goal.

The upper rungs

Higher steps are reached only if earlier ones are tolerated and clinical goals remain unmet, always under provider guidance.

What patients commonly report at each step

Gastrointestinal symptoms — nausea, mild vomiting, transient constipation or diarrhea — are the most commonly reported experiences at any dose step, and they tend to be sharpest in the first weeks after moving to a new one. Appetite suppression, earlier satiety, and changes in meal portions are also frequently described. These are individual experiences, and clinical outcomes vary widely from person to person.

When the next step happens

Titration intervals are specified in each product's FDA label, typically about four weeks between steps, and are then adjusted by the prescribing provider based on tolerability and clinical response. If gastrointestinal symptoms are significant, a provider may hold at the current dose longer. If the current dose is well tolerated but clinical goals are not yet met, the provider may advance per the label.

Side effects to watch for at any rung

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contact a provider for severe or persistent abdominal pain that may signal pancreatitis, right-upper-quadrant pain with fever that may signal gallbladder disease, persistent vomiting with dehydration, signs of hypoglycemia, or any allergic reaction. Severe symptoms warrant urgent or emergency care.

How to use a dosage chart wisely

A dosage chart is a reference, and it works best as a conversation aid rather than a self-guided plan. Reading where the steps sit can help you understand what your provider is describing and what a future increase might involve, which makes appointments more productive. It is not, however, a tool for adjusting on your own; the schedule shows minimum intervals and an ordered sequence, but the decision to hold, advance, or pause belongs to the clinician who knows your tolerability and goals. Used that way, the chart demystifies the process without inviting guesswork. Bring specific observations about how each step has felt, and let the chart frame questions you ask rather than instructions you follow, since your provider translates the general schedule into your particular plan.

Why two people on the same chart differ

A dosage chart is identical for everyone, but the experience of it is not, because biology varies. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology. It is not a pharmacogenomic test and never predicts response to any specific dose or medication; it offers upstream context that applies at every rung. Explore the broader Weight Management Protocols for how PlexusDx frames that context. PlexusDx does not sell other GLP-1 category compounds such as retatrutide, which is investigational and not FDA-approved.

Frequently Asked Questions

How is the tirzepatide titration schedule structured?

Per the FDA-approved label, tirzepatide is titrated starting at 2.5 mg weekly and moving through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals. A dosage chart simply displays these ordered steps; your prescribing provider decides where your dose fits based on tolerability and clinical response.

How long do people stay at one step?

Titration intervals in the FDA label are typically a minimum of about four weeks between steps, then modified by the prescribing provider based on tolerability and response. Some patients remain at one dose long-term as a maintenance dose; others continue advancing along the label schedule under provider guidance.

What side effects should I watch for at any step?

Gastrointestinal symptoms — nausea, vomiting, diarrhea, constipation — are most common at any step. Contact your provider for severe abdominal pain, persistent vomiting with dehydration, right-upper-quadrant pain with fever, or any allergic reaction. All GLP-1 pathway compounds carry the class boxed warning for thyroid C-cell tumor risk.

Does a genetic test tell me which dose I need?

No. The Precision Peptide Genetic Test does not predict response to any specific dose or medication. It analyzes pathway-level variants in genes like FTO, GLP1R, MC4R, and TCF7L2 that shape baseline metabolism, offering upstream context that applies across the titration schedule rather than a dosing recommendation.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic-health explainers.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.